MACROGENICS INC

MGNX

MACROGENICS INC

MGNX

Insider Sentiment (TTM):

Last Purchase:2025-08-20Last Sale:2025-02-15Shares Purchased (TTM):0Shares Sold (TTM):0

Institutional Sentiment:

As of:2026-03-31Institutional Shares Owned:40,153,614Shares Outstanding:63,449,780Institutional Ownership Pct.:63.28%

Earnings Market Reaction:

Filing Date:2026-08-14Price on Filing Date:N/APrevious Close:N/A% Change:N/A

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Financial Statements

10‑Q10‑K

Values in Millions ($)	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30
Assets
Assets Current
Cash And Cash Equivalents At Carrying Value	114	67	57	80	131	146	183	180	84	80	101	90
Investments	59	88	133	66	46	9	19	21	56	104	129	167
Accounts Receivable Net Current	25	10	13	69	13	11	4	9	6	7	10	25
Inventory Net	-	9	8	9	9	9	0	3	1	1	1	1
Prepaid Expense And Other Assets Current	4	8	9	8	7	8	12	10	9	10	10	9
Assets Current	322	183	220	232	205	182	217	222	157	203	251	291
Property Plant And Equipment Net	2	11	13	14	15	17	18	19	20	21	22	23
Operating Lease Right Of Use Asset	21	22	23	23	24	24	25	22	23	23	24	25
Other Assets Noncurrent	0	1	1	1	1	1	2	1	1	1	1	1
Assets	345	218	257	271	245	225	262	264	201	248	298	340
Liabilities And Stockhold…
Liabilities Current
Accounts Payable Current	3	4	5	6	5	7	5	7	5	11	6	3
Accrued Liabilities Current	30	18	22	23	21	28	29	25	24	18	24	25
Contract With Customer Liability Current	56	68	11	10	8	16	16	23	24	23	22	19
Operating Lease Liability Current	5	5	5	5	5	5	5	5	4	4	4	4
Liabilities Current	109	96	43	44	39	55	56	59	58	56	56	51
Contract With Customer Liability Noncurrent	0	0	56	56	56	56	56	56	56	56	59	64
Operating Lease Liability Noncurrent	30	31	32	32	32	32	33	29	30	30	30	30
Other Liabilities Noncurrent	0	1	1	1	2	2	2	0	0	0	0	0
Liabilities	303	197	201	204	199	145	146	144	143	142	146	146
Stockholders Equity
Common Stock Value	1	1	1	1	1	1	1	1	1	1	1	1
Additional Paid In Capital Common Stock	1,304	1,302	1,299	1,297	1,293	1,289	1,285	1,274	1,268	1,261	1,255	1,250
Accumulated Other Comprehensive Income Loss Availa…	-0	-0	0	0	-0	-0	0	0	-0	-0	-0	-0
Retained Earnings Accumulated Deficit	-1,262	-1,281	-1,244	-1,230	-1,247	-1,211	-1,170	-1,154	-1,211	-1,155	-1,103	-1,057
Stockholders Equity	43	21	56	67	47	79	116	120	58	106	153	194
Liabilities And Stockholders Equity	345	218	257	271	245	225	262	264	201	248	298	340
Common Stock Par Or Stated Value Per Share	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01
Common Stock Shares Authorized	125	125	125	125	125	125	125	125	125	125	125	125
Shares Outstanding	64	64	63	63	63	63	63	63	63	63	62	62

Subscribe to unlock 17+ years of financial data, unlimited metrics, and saved tables

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, and saved tables

Start free trial

Custom Table

10‑Q10‑K

0/5

Search a metric to start building a table

Subscribe to unlock 17+ years of financial data, unlimited metrics, transformations, and saved visuals

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, transformations, and saved visuals

Start free trial

Interactive Financial Visualizations

10‑Q10‑K

Stock Price:

OnOff

Transformations:

0/1

Search a metric to start building a visual

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Earnings Market Reaction

10‑Q10‑K

Fiscal Year	Q1 1 Month	Q1 2 Month	Q1 3 Month	Q2 1 Month	Q2 2 Month	Q2 3 Month	Q3 1 Month	Q3 2 Month	Q3 3 Month	Q4 1 Month	Q4 2 Month	Q4 3 Month
2026	13.33%	36.52%	9.57%	-	-	-	-	-	-	-	-	-
2025	15.58%	-5.19%	2.60%	23.46%	9.88%	2.47%	-6.80%	9.52%	24.49%	30.08%	32.63%	76.27%
2024	-72.12%	-71.03%	-62.17%	-3.57%	-12.36%	-4.12%	-4.77%	-14.32%	-14.32%	-38.57%	-31.90%	-15.24%
2023	-	-	-	-	-	-	54.04%	76.84%	143.01%	-28.23%	-29.01%	-77.82%
Earnings Market Reaction data beyond 3 years is for subscribers only. Unlock the full earnings market reaction history Start 7-day free trial

Subscribe to unlock 17+ years of financial data and 90+ calculated metrics

Start 7-day free trial

Subscribe to unlock 17+ years of data and 90+ calculated metrics

Start free trial

Performance and Valuation Metrics

Rows marked with a lock icon are subscribers only — subscribe to unlock 90+ calculated metrics and 17+ years of history.

Metrics	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30
Liquidity Ratios
Current Ratio	2.96	1.90	5.10	5.22	5.26	3.28	3.92	3.75	2.71	3.63	4.48	5.68
Quick Ratio	2.92	1.72	4.71	4.85	4.85	2.97	3.71	3.53	2.53	3.43	4.28	5.49
Working Capital	212.87M	86.58M	176.83M	187.62M	165.95M	126.65M	161.96M	162.89M	99.05M	146.81M	195.23M	240.03M
Leverage & Debt
Debt to Equity	7.06	9.28	3.62	3.04	4.26	1.84	1.25	1.20	2.48	1.34	0.96	0.75
Interest Coverage TTM	-2.72	-7.05	-17.20	-28.19	-92.14	-821.92	-95.08	-94.02	-172.77	-96.26	-117.65	-74.76
Debt Ratio	0.88	0.90	0.78	0.75	0.81	0.65	0.56	0.55	0.71	0.57	0.49	0.43
Efficiency & Turnover
Asset Turnover TTM	0.66	0.77	0.63	0.42	0.67	0.65	0.54	0.47	0.16	0.15	0.20	0.45
Days Sales Outstanding TTM	34.53	22.47	19.83	126.78	22.76	21.04	17.86	43.98	56.07	182.59	206.85	58.98
Receivables Turnover TTM	10.57	16.24	18.40	2.88	16.04	17.35	20.44	8.30	6.51	2.00	1.76	6.19
Per Share Metrics
Diluted EPS TTM	-0.23	-1.11	-1.18	-1.20	-0.58	-0.89	-1.07	-1.55	-2.18	-0.37	-0.15	0.80
Free Cash Flow Per Share TTM	-1.20	-1.13	-1.31	-1.86	-0.44	-1.15	-1.15	-0.98	-2.51	-1.83	-1.29	-0.36
Dividend Per Share TTM	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Margin Metrics
Gross Profit Margin TTM	-	-	-	103.57%	100.33%	99.68%	99.44%	99.45%	98.31%	98.21%	98.95%	99.53%
Operating Profit Margin TTM	-17.47%	-37.38%	-44.77%	-106.95%	-56.28%	-64.56%	-73.74%	-75.78%	-479.76%	-423.39%	-286.38%	-88.26%
Net Profit Margin TTM	-7.44%	-41.32%	-45.87%	-67.60%	-24.25%	-36.23%	-44.66%	-69.07%	-332.47%	-53.60%	-15.42%	41.13%
Growth Metrics
Net Revenue Growth (1Y)	30.72%	10.53%	8.49%	-20.57%	265.99%	255.31%	155.26%	16.68%	-73.10%	-73.78%	-61.33%	30.26%
Net Income Growth (1Y)	-59.91%	26.06%	11.43%	-22.26%	-73.31%	140.17%	639.30%	-295.96%	-1,930.74%	-74.55%	-92.44%	-126.14%
EPS Growth (1Y)	-60.20%	25.10%	10.49%	-22.86%	-73.51%	137.59%	631.13%	-293.57%	-1,907.85%	-74.75%	-92.50%	-125.92%
Valuation Metrics
P/E TTM	-20.13	-2.61	-1.36	-1.40	-2.10	-1.43	-3.04	-2.11	-1.95	-39.46	-65.77	5.80
P/B TTM	6.85	8.65	1.83	1.59	1.64	1.01	1.75	1.72	4.61	8.64	3.90	1.49
P/S TTM	1.50	1.08	0.62	0.95	0.51	0.52	1.36	1.46	6.49	21.15	10.14	2.38
Market Cap	293.81M	183.37M	101.68M	106.23M	76.39M	79.97M	203.52M	206.43M	266.32M	916.92M	595.76M	288.83M
Enterprise Value	179.90M	116.85M	44.46M	26.10M	-54.29M	-65.60M	20.68M	26.80M	182.39M	836.56M	494.80M	198.93M
Calculated Values
Free Cash Flow TTM	-76.62M	-71.69M	-82.95M	-117.87M	-27.69M	-72.40M	-72.08M	-61.71M	-157.02M	-113.88M	-79.97M	-22.39M
Net Debt	-113.91M	-66.52M	-57.22M	-80.13M	-130.69M	-145.57M	-182.84M	-179.63M	-83.93M	-80.36M	-100.96M	-89.90M
Per-Share and Margin
EPS TTM
Adjusted EPS TTM
Cash Flow Per Share TTM
Pretax Margin TTM
Stock Comp to Revenue TTM
Turnover Ratios and Averages
Average Assets
Average Equity
Average Inventory
Average Receivables
Average Accounts Payables
Inventory Turnover TTM
Payables Turnover TTM
Days Inventory Outstanding TTM
Days Payables Outstanding TTM
Cash Conversion Cycle TTM
Working Capital to Revenue
Deferred Revenue to Revenue
Growth Rates
Total Assets Growth (1Y)
Total Assets Growth (3Y)
Total Assets Growth (5Y)
Dividends Paid Growth (1Y)
Dividends Paid Growth (3Y)
Dividends Paid Growth (5Y)
EPS Growth (3Y)
EPS Growth (5Y)
Net Income Growth (3Y)
Net Income Growth (5Y)
Net Profit Margin Growth (1Y)
Net Profit Margin Growth (3Y)
Net Profit Margin Growth (5Y)
Net Revenue Growth (3Y)
Net Revenue Growth (5Y)
Deferred Revenue Growth (1Y)
Retained Earnings Growth (1Y)
Credit, Liquidity, Returns, Payout
Cash Ratio
Net Working Capital
Debt to EBITDA TTM
Net Debt to EBITDA TTM
Net Debt to Equity
Altman A
Altman B
Altman C
Altman D
Altman E
Altman Z-Score
ROA TTM
ROE TTM
NOPAT TTM
ROIC TTM
Effective Tax Rate TTM
Payout Ratio TTM
Dilution Ratio
Retained Earnings to Equity
Treasury Stock to Equity
Treasury Stock Change (1Y)
Accrued to Current Liabilities
NCAV
NCAV Per Share TTM
Valuation Ratios
P/CF TTM
PEG Ratio
Dividend Yield TTM
Free Cash Flow Yield TTM
EV EBITDA TTM
EV EBIT TTM
EV Revenue TTM
EV FCF TTM
Stock Compensation TTM
Adjusted Net Income TTM
Billings TTM
Total Debt
Invested Capital

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Insider Transactions

2025-08-20Purchase

Owner: Heiden, William K

Title: -

Shares: 49,500

Price/Share: $1.49

Value: $73,755.00

Shares Owned: 111,000

Relationship: Director

Ownership: Direct

2025-02-15Sale

Owner: Smith, Beth Ann

Title: VP, Controller & Treasurer

Shares: 423

Price/Share: $2.56

Value: $1,082.88

Shares Owned: 9,532

Relationship: Officer

Ownership: Direct

2024-04-04Sale

Owner: Peters, Jeffrey Stuart

Title: Senior VP and General Counsel

Shares: 51,395

Price/Share: $16.58

Value: $852,129.10

Shares Owned: -

Relationship: Officer

Ownership: Direct

2024-03-06Sale

Owner: Peters, Jeffrey Stuart

Title: Senior VP and General Counsel

Shares: 19,625

Price/Share: $21.50

Value: $421,937.50

Shares Owned: 8,895

Relationship: Officer

Ownership: Direct

2024-03-04Sale

Owner: Karrels, James

Title: SVP, CFO and Secretary

Shares: 30,000

Price/Share: $20.50

Value: $615,000.00

Shares Owned: 171,452

Relationship: Officer

Ownership: Direct

Filed Date	Owner	Relationship	Title	Ownership	Purchase/Sale	No. Shares	Price Per Share	Value	Shares Owned	Document Type
2025-08-20	Heiden, William K	Director	-	Direct	Purchase	49,500	1.49	$73,755.00	111,000	4
2025-02-15	Smith, Beth Ann	Officer	VP, Controller & Treasurer	Direct	Sale	423	2.56	$1,082.88	9,532	4
2024-04-04	Peters, Jeffrey Stuart	Officer	Senior VP and General Counsel	Direct	Sale	51,395	16.58	$852,129.10	0	4
2024-03-06	Peters, Jeffrey Stuart	Officer	Senior VP and General Counsel	Direct	Sale	19,625	21.50	$421,937.50	8,895	4
2024-03-04	Karrels, James	Officer	SVP, CFO and Secretary	Direct	Sale	30,000	20.50	$615,000.00	171,452	4
2024-03-04	Risser, Eric Blasius	Officer	Chief Operating Officer	Direct	Sale	41,159	19.81	$815,359.79	38,900	4
2024-03-04	Spitznagel, Thomas	Officer	Sr VP, Technical Ops	Direct	Sale	10,000	20.00	$200,000.00	8,316	4
2024-02-26	Peters, Jeffrey Stuart	Officer	Senior VP and General Counsel	Direct	Sale	16,124	17.22	$277,655.28	8,895	4
2024-02-07	Bonvini, Ezio	Officer	Sr VP, Research & CSO	Direct	Sale	3,334	18.00	$60,012.00	71,334	4
2024-02-05	Peters, Jeffrey Stuart	Officer	Senior VP and General Counsel	Direct	Sale	76,251	16.50	$1,258,141.50	0	4
2024-02-01	Bonvini, Ezio	Officer	Sr VP, Research & CSO	Direct	Sale	13,316	15.00	$199,740.00	74,668	4
2024-01-19	Bonvini, Ezio	Officer	Sr VP, Research & CSO	Direct	Sale	13,316	12.00	$159,792.00	87,984	4
2023-12-20	Bonvini, Ezio	Officer	Sr VP, Research & CSO	Direct	Sale	18,880	10.08	$190,310.40	101,300	4
2023-10-02	Bb, Biotech Ag, Biotech T…	TenPercentOwner	-	Direct	Purchase	150,000	4.46	$669,000.00	9,929,963	4
2023-09-07	Biotech, Target N V, Bb B…	TenPercentOwner	-	Direct	Purchase	200,000	5.26	$1,052,000.00	9,779,963	4
2023-08-30	Hurwitz, Edward	Director	-	Direct	Purchase	15,000	4.91	$73,650.00	33,074	4
2023-03-10	Peters, Jeffrey Stuart	Officer	Senior VP and General Counsel	Direct	Sale	5,372	6.03	$32,393.16	0	4
2023-02-14	Bb, Biotech Ag, Biotech T…	TenPercentOwner	-	Direct	Purchase	500,000	5.07	$2,535,000.00	9,579,963	4
2023-01-19	Biotech, Target N V, Bb B…	TenPercentOwner	-	Direct	Purchase	150,000	5.30	$795,000.00	9,079,963	4
2022-12-27	Bb, Biotech Ag, Biotech T…	TenPercentOwner	-	Direct	Purchase	200,000	5.61	$1,122,000.00	8,929,963	4
2022-11-22	Biotech, Target N V, Bb B…	TenPercentOwner	-	Direct	Purchase	300,000	5.96	$1,788,000.00	8,529,963	4
2022-10-24	Bb, Biotech Ag, Biotech T…	TenPercentOwner	-	Direct	Purchase	250,000	4.36	$1,090,000.00	8,229,963	4
2022-10-20	Bb, Biotech Ag, Biotech T…	TenPercentOwner	-	Direct	Purchase	285,977	4.00	$1,143,908.00	7,729,963	4
Additional insider transactions are for subscribers only. Unlock the complete Form 4 filing history Start 7-day free trial

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Institutional Ownership

No data available for chart

2026-03-31

63.28%

Inst. Shares: 40,153,614

Shares Outstanding: 63,449,780

2025-12-31

58.08%

Inst. Shares: 36,681,860

Shares Outstanding: 63,155,096

2025-09-30

68.46%

Inst. Shares: 43,290,492

Shares Outstanding: 63,233,266

2025-06-30

72.07%

Inst. Shares: 45,499,642

Shares Outstanding: 63,136,057

2025-03-31

80.61%

Inst. Shares: 50,758,574

Shares Outstanding: 62,965,415

Date	Institutional Shares Owned	Shares Outstanding	Institutional Ownership %
2026-03-31	40,153,614	63,449,780	63.28%
2025-12-31	36,681,860	63,155,096	58.08%
2025-09-30	43,290,492	63,233,266	68.46%
2025-06-30	45,499,642	63,136,057	72.07%
2025-03-31	50,758,574	62,965,415	80.61%
2024-12-31	53,770,994	62,621,185	85.87%
2024-09-30	52,949,791	62,744,005	84.39%
2024-06-30	58,582,194	62,663,677	93.49%
2024-03-31	58,225,486	62,290,538	93.47%
2023-12-31	53,739,930	61,929,198	86.78%
2023-09-30	49,549,089	61,980,680	79.94%
2023-06-30	51,720,577	61,880,096	83.58%
Additional institutional holders are for subscribers only. Unlock the complete Form 13F ownership history Start 7-day free trial

MACROGENICS INC (MGNX) — SEC Financial Statements & Analysis

MACROGENICS INC (MGNX) is a pharmaceutical preparations company, incorporated in DE. MACROGENICS INC trades on Nasdaq as: MGNX. Based on its latest SEC filing (Form 10-Q, period ending 2026-06-30), MACROGENICS INC reported a 30.72% year-over-year revenue growth, a Gross Profit Margin of 103.57% (TTM), a Debt-to-Equity ratio of 7.06x, a Price-to-Sales (P/S) ratio of 1.50x (TTM), a Price-to-Book (P/B) ratio of 6.85x (TTM), at a market cap of $293.81M. Figures below are sourced from SEC EDGAR, as-filed.

Net Revenue TTM Growth 1Y: 30.72%
Gross Profit Margin TTM: 103.57%
Debt To Equity: 7.06x
P/S TTM: 1.50x
P/B TTM: 6.85x
Market Cap: $293.81M

Data as of 2026-06-30 · Source: SEC EDGAR

Frequently Asked Questions

What industry is MACROGENICS INC in?

MACROGENICS INC (MGNX) operates in the Pharmaceutical Preparations industry.

What is MGNX's market cap?

MACROGENICS INC (MGNX) has a market capitalization of $293.81M as of 2026-06-30.

What exchange does MGNX trade on?

MACROGENICS INC (MGNX) trades on the Nasdaq.

Where is MACROGENICS INC incorporated?

MACROGENICS INC is incorporated in DE.

MACROGENICS INC

Financial Statements

Custom Table

Interactive Financial Visualizations

Earnings Market Reaction

Performance and Valuation Metrics

Insider Transactions

Institutional Ownership

MACROGENICS INC (MGNX) — SEC Financial Statements & Analysis

Frequently Asked Questions

Companies in Pharmaceutical Preparations

Wall Street's data.
Main Street's price.

MACROGENICS INC (MGNX) — SEC Financial Statements & Analysis

Frequently Asked Questions

Companies in Pharmaceutical Preparations

Wall Street's data.Main Street's price.

Wall Street's data.
Main Street's price.